News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pharmatech Oncology to Present at 46th Annual Drug Information Association Meeting


6/11/2010 9:35:37 AM

DENVER, June 11 /PRNewswire/ -- On Wednesday June 16, Pharmatech Oncology will chair a session at the 46th Annual DIA Meeting to discuss patient-focused clinical research systems in the age of personalized cancer medicine. Speakers will include Jeffrey Vacirca MD, Director of Clinical Research at North Shore Hematology/Oncology Associates in East Setauket, NY and Matt Baker, President and CEO of Compass IRB in Mesa, AZ.

Dr. Vacirca will discuss the concept of personalized cancer research by reevaluating the site-based research paradigm and the development of a patient focused solution known as Just-In-Time. Matt Baker will present the development of IRB systems in alignment with the requirements of patient-first research. Furthermore, he will discuss protection of patient rights and regulatory compliance in the modern research setting. Session chair, Eric Lynam, VP of Business Development at Pharmatech Oncology, comments, "This is a very exciting period in cancer therapeutic research, and the time is at hand to personalize the clinical research process as we focus increasingly on precision cancer medicine. This session is intended to stimulate discussion and new ideas among pharmaceutical companies, research organizations, physicians, patients, and patient advocates, with a goal toward putting patients first in clinical trials and developing solutions to bring better cancer medicines into the clinic faster."

The Just-In-Time solution is a patient-focused approach that enables research centers to proactively look for clinical trial candidate patients prior to study initiation. Once a potential study patient is identified (using standard-of-care procedures), the site is initiated in an expedited manner. In spite of the challenges involved in clinical trials for patients with rare cancers, Just-In-Time continues to demonstrate that US-based studies can accrue efficiently, while significantly mitigating cost and time related risks. This methodology represents an important step toward a more effective clinical trial system, aligned with the needs of precision cancer treatment. Just-In-Time continues to evolve, setting a new standard for time to first patient enrolled, enrollment rate, and overall patient accrual.

Pharmatech Oncology, headquartered in Denver, Colorado, is a Research Management Organization (RMO) dedicated to the highest quality of clinical research. Pharmatech Oncology provides oncology-specific Site Management Organization (SMO) and Contract Research Organization (CRO) services to its network of primarily community-based clinics. While experienced in oncology studies, the company's separate Data Management business entity is also capable of providing services for research projects in other disease indications. Pharmatech Oncology's dedication to rapid enrollment and quality data ensures successful development and utilization of therapeutic products among sponsors, investigators, and patients.

About Pharmatech Oncology, Inc.:

Pharmatech Oncology, headquartered in Denver, Colorado, is a Research Management Organization (RMO) dedicated to the highest quality of clinical research. Pharmatech Oncology provides oncology-specific Site Management Organization (SMO) and Contract Research Organization (CRO) services to its network of primarily community-based clinics. While experienced in oncology studies, the company's separate Data Management business entity is also capable of providing services for research projects in other disease indications . Pharmatech Oncology's dedication to rapid enrollment and quality data ensures successful development and utilization of therapeutic products among sponsors, investigators, and patients.

For more information about Pharmatech, please visit www.pharmatechoncology.com.

For more information about Compass IRB, please visit www.compassirb.com

Key words: Cancer, clinical trials, contract research, oncology, patients, research, site management

SOURCE Pharmatech Oncology, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES